세계의 eClinical 솔루션 시장 - 제품별, 배포 모델별, 용도별, 임상시험 단계별, 최종 사용자별, 지역별 : 전망(-2029년)

The global eClinical solutions market is projected to reach USD 22.1 billion by 2029 from USD 11.6 billion in 2024, at a high CAGR of 13.7% during the forecast period. Growth Drivers include the rising operational costs and regulatory obligations for all clinical research studies, adoption of innovative software solutions for clinical research, favourable government funding received for clinical trials, rising need for better standardization and quality of clinical data, and growing R&D expenditure on drug development by pharmaceutical-biotech companies. There are some inhibitive factors, such as the high rate of implementation of eClinical solutions, scarcity of skilled professionals to implement and manage these solutions, and inadequate awareness about the benefits of eClinical solutions among researchers.

"In 2023, data collection segment constituted the largest segment in the eClinical solutions market, by application."

In 2023, the data collection segment accounted for the biggest proportion of the eClinical solutions market, by application. This growth is primarily driven by solutions such as electronic data capture (EDC) systems, which streamline the process by reducing manual errors, speeding up data entry, and allowing for real-time access to data; the growing need to comply with stringent regulatory standards and support remote and decentralised trials; and its growing importance in clinical trial success, as it ensures the integrity and quality of the data being gathered.

"In 2023, the pharmaceutical & biopharmaceutical companies held the largest market share among end users."

In 2023, pharmaceutical and biopharmaceutical firms accounted for the highest proportion of the eClinical solutions market by end user. This dominance stems primarily from the enormous number of corporations' investments in clinical trials and drug development. These companies run numerous clinical studies to get their innovative medications and cures to market, necessitating significantly improved eClinical systems to manage the complicated processes involved. Furthermore, these organizations have significant financial resources to invest in eClinical solutions, allowing them to adopt cutting-edge technology and developments, hence, fueling the industry.

"In 2023, North America was the largest regional market for eClinical solutions market."

In 2023, North America had the highest share of the eClinical Solutions market. This segment's highest share is attributed to its advanced healthcare infrastructure, major R&D investments, and strict regulatory environment. Big Pharma companies like Pfizer and Johnson & Johnson that conduct clinical trials on a large scale are the ones responsible for the high demand of these solutions. The region's high digital literacy and technological innovation given by companies such as Medidata Solutions propel the widespread use of eClinical solutions. The availability of regulatory frameworks, such as the FDA's 21 CFR Part 11, ensures compliance while driving up demand for sophisticated data management and clinical trial solutions.

The break-down of primary participants is as mentioned below:

• By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
• By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
• By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

Key Players in the eClinical Solutions Market

The key players functioning in the EClinical solutions market include Medidata (A Dassault Systemes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).

Research Coverage:

The report analyses the eClinical solutions market. It aims to estimate the market size and future growth potential of various market segments based on product, deployment model, application, clinical trial phase, end-user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers: (increasing operational costs and regulatory requirements associated with clinical research studies), restraints (high implementation costs associated with eClinical solutions), opportunities (growing number of clinical trials in developing nations), and challenges (concerns pertaining to patient privacy) influencing the growth of the eClinical solutions market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the eClinical solutions market.
• Market Development: Comprehensive information on the lucrative emerging markets, products, deployment models, applications, clinical trial phase, end-users, and regions.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the eClinical solutions market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the eClinical solutions market like Medidata (A Dassault Systemes Company) (France), Veeva Systems (US), IQVIA Inc. (US), ICON plc (Ireland), Oracle (US), Signant Health (US), Clario (US), and eClinical Solutions (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES
  • 1.5.1 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Insights from primary experts
• 2.2 MARKET SIZE ESTIMATION
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE AND COUNTRY, 2024
• 4.3 ECLINICAL SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 ECLINICAL SOLUTIONS MARKET REGIONAL MIX
• 4.5 ECLINICAL SOLUTIONS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing focus on cost-effective processes
    • 5.2.1.2 Favorable government support and funding
    • 5.2.1.3 Need for data standardization
    • 5.2.1.4 Increasing R&D expenditure on drug development
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High implementation costs
    • 5.2.2.2 Lack of skilled professionals
    • 5.2.2.3 Limited awareness among researchers
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing number of clinical trials
    • 5.2.3.2 Outsourcing of clinical trials
    • 5.2.3.3 Gradual shift toward real-time data analysis
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Limited adoption in developing and underdeveloped countries
    • 5.2.4.2 Software reliability issues
    • 5.2.4.3 Patient privacy concerns
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 HEALTHCARE PROVIDERS
  • 5.3.2 CLOUD PROVIDERS
  • 5.3.3 GOVERNMENT AGENCIES AND REGULATORY BODIES
  • 5.3.4 ECLINICAL SOLUTION COMPANIES
• 5.4 CASE STUDY ANALYSIS
  • 5.4.1 ENHANCED PATIENT RECORDS USING MEDIDATA ECOA APP
  • 5.4.2 IMPROVED ALZHEIMER'S TREATMENT WITH LEQEMB THERAPY
  • 5.4.3 EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 BARGAINING POWER OF SUPPLIERS
  • 5.6.2 BARGAINING POWER OF BUYERS
  • 5.6.3 THREAT OF SUBSTITUTES
  • 5.6.4 THREAT OF NEW ENTRANTS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 REGULATORY LANDSCAPE
  • 5.7.1 REGULATORY ANALYSIS
    • 5.7.1.1 North America
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
    • 5.7.1.4 Latin America
    • 5.7.1.5 Middle East & Africa
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.8 PATENT ANALYSIS
  • 5.8.1 PATENT PUBLICATION TRENDS FOR ECLINICAL SOLUTIONS
  • 5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 AI-enabled and integrated platforms
    • 5.9.1.2 Clinical data integration
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Cloud computing
    • 5.9.2.2 Analytical tools
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Electronic health records
    • 5.9.3.2 Real-world data
    • 5.9.3.3 Bioinformatics
• 5.10 INDUSTRY TRENDS
  • 5.10.1 DECENTRALIZED CLINICAL TRIALS
  • 5.10.2 TELEMEDICINE
  • 5.10.3 BIG DATA
• 5.11 PRICING ANALYSIS
  • 5.11.1 INDICATIVE PRICING ANALYSIS, BY DEPLOYMENT MODEL
  • 5.11.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 BUYING CRITERIA
• 5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.15 END-USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 INVESTMENT AND FUNDING SCENARIO
• 5.17 IMPACT OF AI/GEN AI ON ECLINICAL SOLUTIONS MARKET
  • 5.17.1 KEY USE CASES
  • 5.17.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.17.2.1 Case study
    • 5.17.2.2 Clinical trial management system market
    • 5.17.2.3 Clinical trial market
    • 5.17.2.4 Electronic clinical outcome assessment solution market
  • 5.17.3 USER READINESS AND IMPACT ASSESSMENT
    • 5.17.3.1 User readiness
      • 5.17.3.1.1 Pharmaceutical and biopharmaceutical companies
      • 5.17.3.1.2 Contract research organizations
    • 5.17.3.2 Impact assessment
      • 5.17.3.2.1 User A: Pharmaceutical & biopharmaceutical companies
        • 5.17.3.2.1.1 Implementation
        • 5.17.3.2.1.2 Impact
      • 5.17.3.2.2 User B: Academic research institutes
        • 5.17.3.2.2.1 Implementation
        • 5.17.3.2.2.2 Impact

6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SOLUTIONS
  • 6.2.1 RISING NEED TO REDUCE TIME AND COSTS IN CLINICAL TRIALS TO ENCOURAGE GROWTH
• 6.3 CLINICAL TRIAL MANAGEMENT SOLUTIONS
  • 6.3.1 RISING DEMAND FOR SITE & DATA COLLECTION SOLUTIONS TO FACILITATE GROWTH
• 6.4 CLINICAL ANALYTICS PLATFORMS
  • 6.4.1 GROWING ADOPTION OF ELECTRONIC MEDICAL RECORDS TO BOOST MARKET
• 6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SOLUTIONS
  • 6.5.1 GROWING TREND OF GLOBALIZATION TO FUEL MARKET
• 6.6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS
  • 6.6.1 INCREASING ADOPTION OF EDIARIES TO AID GROWTH
• 6.7 ELECTRONIC TRIAL MASTER FILE SOLUTIONS
  • 6.7.1 IMPROVED INFORMATION SEARCH AND RETRIEVAL TO FUEL MARKET
• 6.8 ELECTRONIC CONSENT SOLUTIONS
  • 6.8.1 GROWING INCLINATION TOWARD DIGITIZATION TO PROMOTE GROWTH
• 6.9 REGULATORY INFORMATION MANAGEMENT SOLUTIONS
  • 6.9.1 ENHANCED REGULATORY SUBMISSION PROCESS TO AUGMENT GROWTH
• 6.10 CLINICAL DATA INTEGRATION PLATFORMS
  • 6.10.1 GROWING VOLUME OF CLINICAL DATA AND IMPROVED CLOUD TECHNOLOGY TO PROPEL MARKET
• 6.11 SAFETY SOLUTIONS
  • 6.11.1 GROWING ADOPTION OF ECLINICAL SOFTWARE TO SUPPORT MARKET GROWTH
• 6.12 OTHER SOLUTIONS

7 ECLINICAL SOLUTIONS MARKET, BY DEPLOYMENT MODEL

• 7.1 INTRODUCTION
• 7.2 WEB-HOSTED & CLOUD-BASED MODELS
  • 7.2.1 GROWING DEMAND FOR CLOUD-BASED SOLUTIONS TO AUGMENT GROWTH
• 7.3 ON-PREMISE MODELS
  • 7.3.1 MINIMIZED DATA BREACHES AND EXTERNAL ATTACK RISKS TO SUPPORT MARKET

8 ECLINICAL SOLUTIONS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DATA COLLECTION
  • 8.2.1 IMPROVED TRIAL EFFICIENCY TO DRIVE MARKET
• 8.3 DOCUMENT MANAGEMENT & STORAGE
  • 8.3.1 RISING INCLINATION TOWARD STREAMLINED DOCUMENT WORKFLOWS TO FUEL MARKET
• 8.4 SUPPLY MANAGEMENT
  • 8.4.1 NEED TO ADDRESS COMPLEXITIES IN MANAGING CLINICAL TRIAL SUPPLIES TO BOOST MARKET
• 8.5 DATA ANALYTICS
  • 8.5.1 INCREASING NEED FOR OPTIMIZED TRIAL DESIGNS TO AID GROWTH
• 8.6 CLINICAL TRIAL OPERATIONS
  • 8.6.1 GROWING FOCUS ON ENHANCED DRUG DEVELOPMENT TO PROPEL MARKET
• 8.7 REGULATORY INFORMATION MANAGEMENT
  • 8.7.1 EVOLVING GLOBAL REGULATORY STANDARDS TO STIMULATE GROWTH
• 8.8 OTHER APPLICATIONS

9 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE

• 9.1 INTRODUCTION
• 9.2 PHASE I
  • 9.2.1 INCREASING DEMAND FOR ACCURATE CLINICAL DATA MANAGEMENT TO ACCELERATE GROWTH
• 9.3 PHASE II
  • 9.3.1 PUSH TOWARD FASTER DRUG DEVELOPMENT TO FACILITATE GROWTH
• 9.4 PHASE III
  • 9.4.1 INVOLVEMENT OF LARGE PATIENT POPULATION TO ENCOURAGE SEGMENT GROWTH
• 9.5 PHASE IV
  • 9.5.1 GROWING EMPHASIS ON SAFE DRUGS TO DRIVE MARKET

10 ECLINICAL SOLUTIONS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 10.2.1 INCREASING R&D EXPENDITURE TO DRIVE MARKET
• 10.3 CONTRACT RESEARCH ORGANIZATIONS
  • 10.3.1 GROWING OUTSOURCING OF CLINICAL TRIALS TO FUEL MARKET
• 10.4 CONSULTING SERVICE COMPANIES
  • 10.4.1 INCREASING COMPLEXITIES AND COSTS OF CLINICAL DATA MANAGEMENT TO PROPEL MARKET
• 10.5 MEDICAL DEVICE MANUFACTURERS
  • 10.5.1 RISING DEVELOPMENT OF NEW MEDICAL DEVICES TO BOOST MARKET
• 10.6 HOSPITALS & HEALTHCARE PROVIDERS
  • 10.6.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND ECLINICAL SOLUTION PROVIDERS TO STIMULATE MARKET
• 10.7 ACADEMIC & RESEARCH INSTITUTES
  • 10.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO EXPEDITE GROWTH
• 10.8 GOVERNMENT ORGANIZATIONS
  • 10.8.1 INCREASED ADOPTION BY HEALTH DEPARTMENTS AND REGULATORY BODIES TO SPEED UP GROWTH
• 10.9 OTHER END USERS

11 ECLINICAL SOLUTIONS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising government funding for pharmaceutical R&D to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Advanced facilities and shorter approval times for drug candidates to fuel market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 High number of sponsored clinical trials to augment growth
  • 11.3.3 UK
    • 11.3.3.1 Increased investments by pharmaceutical companies to boost market
  • 11.3.4 FRANCE
    • 11.3.4.1 Booming generics market to aid growth
  • 11.3.5 ITALY
    • 11.3.5.1 Favorable drug approval scenario to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Robust network of research centers, universities, and hospitals to encourage growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Low manufacturing costs and huge demand for medicines to expedite growth
  • 11.4.3 INDIA
    • 11.4.3.1 Growing foreign direct investments to facilitate market growth
  • 11.4.4 JAPAN
    • 11.4.4.1 Drug discovery and development initiatives to promote growth
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Higher adoption of advanced digital technologies to stimulate growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Government initiatives to enhance digital infrastructure of healthcare to propel market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Growing modernization initiatives in healthcare sector to support market growth
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 12.3 REVENUE ANALYSIS, 2019-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Product footprint
    • 12.5.5.3 Application footprint
    • 12.5.5.4 End-user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY EVALUATION AND FINANCIAL METRICS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES AND ENHANCEMENTS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 MEDIDATA (A DASSAULT SYSTEMES COMPANY)
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches and enhancements
      • 13.1.1.3.2 Deals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 VEEVA SYSTEMS
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and enhancements
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 IQVIA INC.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 ICON PLC
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches and enhancements
      • 13.1.4.3.2 Deals
  • 13.1.5 ORACLE
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Deals
  • 13.1.6 SIGNANT HEALTH
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches and enhancements
      • 13.1.6.3.2 Deals
  • 13.1.7 CLARIO
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches and enhancements
      • 13.1.7.3.2 Deals
      • 13.1.7.3.3 Other developments
  • 13.1.8 ECLINICAL SOLUTIONS
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches and enhancements
      • 13.1.8.3.2 Deals
  • 13.1.9 CLINION
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches and enhancements
      • 13.1.9.3.2 Deals
  • 13.1.10 MAXISIT
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 4G CLINICAL
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
  • 13.1.12 FOUNTAYN
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 SAAMA
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 MEDNET
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches and enhancements
      • 13.1.14.3.2 Deals
  • 13.1.15 ADVARRA
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches and enhancements
      • 13.1.15.3.2 Deals
  • 13.1.16 CAIDYA
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Deals
      • 13.1.16.3.2 Expansions
  • 13.1.17 OPENCLINICA, LLC
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products offered
    • 13.1.17.3 Recent developments
      • 13.1.17.3.1 Deals
  • 13.1.18 EVIDENTIQ
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products offered
    • 13.1.18.3 Recent developments
      • 13.1.18.3.1 Product launches and enhancements
      • 13.1.18.3.2 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 RESEARCH MANAGER
  • 13.2.2 ANJU SOFTWARE INC.
  • 13.2.3 MEDRIO
  • 13.2.4 CASTOR
  • 13.2.5 REALTIME SOFTWARE SOLUTIONS, LLC
  • 13.2.6 YPRIME, LLC.
  • 13.2.7 VIAL

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS